Elevating the Standard of Care in Wet AMD
Sozinibercept (OPT-302) is poised to transform the wet AMD treatment landscape
and address the unmet medical need for improved efficacy.
Frederic Guerard, PharmD, MS; Arshad M. Khanani, MD, MA, FASRS; Charles C. Wykoff, MD, PhD, FASRS, FACS; and Veeral S. Sheth, MD, MBA, FASRS, FACS
